Drug updated on 11/9/2023
|Tablet (oral; elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: 150mg/150 mg/200 mg/300 mg)
| Ongoing and
- Indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Stribild.
Product Monograph / Prescribing Information
|Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) Prescribing Information
|Gilead Sciences, Inc., Foster City, CA
Systematic Reviews / Meta-Analyses
|Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis.
|JMIR public health and surveillance
|Pre-Exposure Prophylaxis for the Prevention of HIV Infection: A Systematic Review for the U.S. Preventive Services Task Force.
|Agency for Healthcare Research and Quality (US)
|Comparison of 48-week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens: a systematic review and network meta-analysis.
Clinical Practice Guidelines
|Clinical Considerations in the Selection of Preexposure Prophylaxis for HIV Prevention in Canada.
|The Canadian Journal or infectious diseases & medical microbiology
|Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.